Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Plasma Cell Myeloma

What are common treatments for hematopoietic and lymphoid cell neoplasm?

The treatments of lymphoma & leukemia have not changed drastically from the 1980s to the 1990s. Both, chemotherapy and radiotherapy are routinely prescribed to patients, but with small improvement over time..

question: Does new and more promising therapeutic approaches for the treatment of human osteosarcoma : combined use of new small molecules and conventional anticancer agents? answer: Because of small response rates to single therapies, new and more promising approaches for therapy of human osteosarcoma seem to be necessary. Because of the small number of osteosarcoma cells and their short-range migration, it is possible to achieve this effect by applying a new class of the anticancer agents.

What are the signs of hematopoietic and lymphoid cell neoplasm?

Hematopoietic and lymphoid cell neoplasms are associated with unexplained fevers or malaise. Lymphadenopathy or lymphedema may occur. Cutaneous lesions may demonstrate erythema nodosum, plaques, or purpuric eruptions, or may even prove to be a primary hematopoietic or lymphoid tissue neoplasm.

How many people get hematopoietic and lymphoid cell neoplasm a year in the United States?

Every year, around 2.9 million people are diagnosed with HLN in the United States. The cancer occurs mainly in infants and young children (1.0–4.3 years); however, most cases occur among adults (20–44 years of age). The cancer is more common among males (1.4 times more likely). Around 11% of people with HLN die each year. Most (61%), but not all, of them are untreated. More than 50% (49,900 patients) of children and almost a third (30,000) of adults with HLN will continue to have an illness for more than 5 years.

What causes hematopoietic and lymphoid cell neoplasm?

Most of the cancers are caused by the excess proliferation of normal tissues, especially the hematopoietic and lymphoid tissue. These organs are not the source of metastasis in most cases.

What is hematopoietic and lymphoid cell neoplasm?

Lymphomas are generally rare among Caucasians and blacks, but are much more frequent among Chinese. Chronic lymphocytic disorders occur mostly in Western countries, but are most common in the Orient. In the United States solid tumors, leukemia, lymphoma, myeloma, and histiocytosis appear most commonly in Caucasians and blacks. In this country, histiocytosis occurs more often and lymphomas are more frequent among blacks.

Can hematopoietic and lymphoid cell neoplasm be cured?

For hematopoietic and lymphoid cell neoplasm, the cure rate is not high even when standard treatments are given. The cure rate for metastatic patients was comparable with that for patients with localized lesions; however, patients with stage III and IV disease had a longer overall survival.

Has allogeneic hematopoietic stem cell transplantation proven to be more effective than a placebo?

Recent findings of this meta-analysis indicate that HST is no more effective than placebo in GVHD prophylaxis and the GVHD/cITR ratio in patients with advanced hematologic malignancies.

What is allogeneic hematopoietic stem cell transplantation?

It is still uncertain to what extent MHC gene expression in HSCs contribute to MHC-associated GVHD. Furthermore, the usefulness of HSCs from unrelated HLA-mismatched donors for allogeneic HSC transplantation has not yet been proven.

What are the chances of developing hematopoietic and lymphoid cell neoplasm?

The cumulative incidence for HL and ALN was 14.7% and 23.6%, respectively. The cumulative incidence was not statistically significant compared with that in the general population, but the difference was significant in the age> or = 65 yr group (HL: 35.7% vs. 31.8%; ALN: 15.3% vs. 13.9%; p=0.02). In a subgroup study, the cumulative incidence of ALN was statistically significant in women of age<65 yr (31.8% vs. 6.6%; p=0.00), and a significant trend was identified for age>65 yr (15.3% vs. 11.7%; p=0.06).

Does allogeneic hematopoietic stem cell transplantation improve quality of life for those with hematopoietic and lymphoid cell neoplasm?

Allogeneic HSCT improves the quality of life of HR+ and HR- patients with hematopoietic and lymphoid cell neoplasms. Those patients who have a more favorable response to HSCT have better health-related quality of life. This should be considered in selecting patients to receive HSCT.

Who should consider clinical trials for hematopoietic and lymphoid cell neoplasm?

The decision to enroll a patient in a hematopoietic and lymphoid cell neoplasm CLN trial requires consideration of both individual and societal factors. The advantages and disadvantages of clinical trials need to be evaluated in a way that is patient- and clinician-specific and then [defined based on relevant medical evidence and professional guidelines] adjusted based on each person's life expectancy, disease status, and personal preferences.

What is the primary cause of hematopoietic and lymphoid cell neoplasm?

The most common cause of HLN is HHV8-associated MCD. This disorder can develop at any age but is more common in pregnant women and men between 10 and 18 years old. Although women are more likely than men to develop the disorder, men and women with the disorder are at the same risk of death. The treatment of choice for HLN is the use of antiviral agents against HHV8.